



A unique approach to cancer research


Matthew Vander Heiden



science + engineering =  
conquering cancer together

# Brief Koch Institute History

1971



1974



NCI·CC

A Cancer Center Designated by the National Cancer Institute



**Former factory  
dedicated for  
cancer research**

By Stephen Blatt

2011



**NCI** Cancer Center

A Cancer Center Designated by the  
National Cancer Institute





# The Koch Institute at MIT

---



- > 192,000 NASF
- 25 members located in the Koch Institute building
- 32 members located in neighboring buildings
- 2 clinical investigators
- > 700 staff

# Kendall Square and the Boston Technology Cluster






# Koch Institute Mission

---


To develop **new insights** into cancer, as well as **new tools** and **technologies** to better **detect**, **monitor**, and **treat** the disease.








Dan  
Anderson



Angela  
Belcher



Sangeeta  
Bhatia



Michael  
Birnbaum



Jianzhu  
Chen



Michael  
Cima




Paula  
Hammond




Michael  
Hemann



David  
Housman



Omer  
Yilmaz



Michael  
Yaffe



Dane  
Wittrup



Forest  
White



Richard  
Hynes




Darrell  
Irvine



Tyler  
Jacks




Angela  
Koehler



Robert  
Langer



Matthew  
Vander Heiden



Stefani  
Spranger




Phillip  
Sharp



Ram  
Sasisekharan



Scott  
Manalis




Christopher  
Love



Jackie  
Lees

# Cross-Disciplinary Research

---





# The Core Facilities of the Swanson Biotechnology Center



## **Basement:**

High Throughput Sciences

Nanotechnology Materials

Flow Cytometry

Integrated Genomics & Bioinformatics (server)

Zebrafish Facility

Glassware Preparation

Media Preparation




## **Level 1:**

Histology

Biopolymers & Proteomics

Integrated Genomics & Bioinformatics


Preclinical Modeling, Imaging & Testing



## **Level 2:**

Flow Cytometry

Microscopy




## **Level 7:**

Preclinical Modeling, Imaging & Testing




# The Koch Institute Core Facilities

---



Biopolymers  
& Proteomics




Flow Cytometry




Glassware



High Throughput  
Sciences




Histology




Integrated Genomics  
& Bioinformatics




Media Preparation



Microscopy



Nanotechnology  
Materials




Preclinical Modeling,  
Imaging & Testing




Zebrafish

# Koch Institute Focus Areas


---




Detection &  
Monitoring




Metastasis



Precision  
Medicine



Nano-Based  
Drug Delivery



Immune-  
oncology

cross-cutting themes traversing multiple cancer types  
and applied at all stages of the research pipeline



# Koch Institute Signature Programs and Centers

---



FRONTIER RESEARCH PROGRAM



MIT  
STEM  
CELL  
INITIATIVE



MIT CENTER FOR  
**PRECISION  
CANCER MEDICINE**

LUDWIG  
CANCER  
RESEARCH



# The Bridge Project

---




- > Philanthropically funded
- > Collaborative partnership with Dana-Farber/ Harvard Cancer Center



# Measuring Biophysical Properties of Single Cells

## Suspended Microchannel Resonator (SMR)




*Burg et al. Nature 2007*

Resonant frequency shift is directly proportional to single-cell buoyant mass

Precision is  $<0.1\%$  (50 femtograms)

## Serial SMR Array





*Cermak et al. Nature Biotech. 2016*


Mass accumulation rate



THE BRIDGE PROJECT




# Mass accumulation rate as a predictive biomarker






# Tumor Oxygen Measurements to Guide Therapy for Cervical Cancer Patients




- Poor clinical outcomes for low oxygen tumors and low oxygen tumors are known to be more resistant to radiation therapy
- New clinical device: oxygen sensor that may guide where to increase brachytherapy radiation dose to tumors with low oxygen levels
- First MR guided HDR brachytherapy with oxygen sensor performed July 2019

## Clinical Implementation




Clinical Oxygen  
Sensor Design




For High Dose  
Brachytherapy



# Activity-Based Nanosensors for Disease Monitoring and Detection




# Imaging extracellular matrix changes to detect cancer



## KPC GEMM with PanIN





## Proteomic analyses of ECM





# Microdevices to assess drug response


---



Robert Langer, Michael Cima, Oliver Jonas (KI)

# Microdevices to assess drug response


---



Davidson et al., Nature Med, 2017

# Improving Early Detection of Breast Cancer

---



## **New federal law requires mammography providers to send breast density notifications**

*Michael Walter* | February 19, 2019 | *Policy*



When President Donald Trump signed a federal funding bill into law on Feb. 15, it included text that said that all mammography providers must include updated information about breast density in reports sent to both patients and their physicians.



# Breast Density Assessments Vary even Among Expert Radiologists

---

**Annals of Internal Medicine**

ORIGINAL RESEARCH

## Variation in Mammographic Breast Density Assessments Among Radiologists in Clinical Practice

### A Multicenter Observational Study



Brian L. Sprague, PhD; Emily F. Conant, MD; Tracy Onega, PhD; Michael P. Garcia, MS; Elisabeth F. Beaber, PhD; Sally D. Herschorn, MD; Constance D. Lehman, MD, PhD; Anna N.A. Tosteson, ScD; Ronilda Lacson, MD, PhD; Mitchell D. Schnall, MD, PhD; Despina Kontos, PhD; Jennifer S. Haas, MD, MSc; Donald L. Weaver, MD; and William E. Barlow, PhD; on behalf of the PROSPR Consortium\*

**Results:** Overall, 36.9% of mammograms were rated as showing dense breasts. Across radiologists, this percentage ranged from 6.3% to 84.5% (median, 38.7% [interquartile range, 28.9% to 50.9%]), with multivariable adjustment for patient characteristics having little effect (interquartile range, 29.9% to 50.8%).

# KI Contribution: Density Assessment Using Deep Learning



## Mammographic Breast Density Assessment Using Deep Learning: Clinical Implementation

*Constance D. Lehman, MD, PhD • Adam Yala, MEng • Tal Schuster, MSc • Brian Dontchos, MD • Manisha Bahl, MD, MPH • Kyle Swanson, BS • Regina Barzilay, PhD*



# Clinical Implementation


---






# Can AI Predict Future Breast Cancer?

---



# KI Founded Biotechnology Companies





**KOCH**INSTITUTE  
for Integrative Cancer Research at MIT

science + engineering = conquering cancer together

[ki.mit.edu](http://ki.mit.edu)

